6-((trans-4-(2-fluoro-3-(trifluorometh-yl)phenoxy)-1-(5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)cyclohexyl)methyl)-N-1H-pyrazol-3-ylpyridin-2-amine trifluoroacetate

ID: ALA3964756

PubChem CID: 87251852

Max Phase: Preclinical

Molecular Formula: C26H24F7N7O4

Molecular Weight: 517.49

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: N=c1[nH]nc([C@]2(Cc3cccc(Nc4cc[nH]n4)n3)CC[C@@H](Oc3cccc(C(F)(F)F)c3F)CC2)o1.O=C(O)C(F)(F)F

Standard InChI: InChI=1S/C24H23F4N7O2.C2HF3O2/c25-20-16(24(26,27)28)4-2-5-17(20)36-15-7-10-23(11-8-15,21-34-35-22(29)37-21)13-14-3-1-6-18(31-14)32-19-9-12-30-33-19;3-2(4,5)1(6)7/h1-6,9,12,15H,7-8,10-11,13H2,(H2,29,35)(H2,30,31,32,33);(H,6,7)/t15-,23-;

Standard InChI Key: FANGKPWHJNTCJK-IGVGDGLPSA-N

Molfile:

     RDKit          2D

 44 47  0  0  0  0  0  0  0  0999 V2000
   31.5830  -14.0207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.2975  -13.6082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.0119  -14.0207    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   32.2975  -12.7832    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   30.8685  -13.6082    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   31.5830  -14.8457    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   30.8663  -14.4290    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   24.0817  -10.7582    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.0805  -11.5855    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.7953  -11.9984    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.5117  -11.5850    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.5089  -10.7546    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.7935  -10.3454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.2218  -10.3394    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   26.9378  -10.7491    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.9383  -11.5759    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.6502  -11.9856    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.3656  -11.5739    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.3644  -10.7480    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.6479  -10.3337    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0800  -11.9864    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0799  -12.8114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.3655  -13.2195    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.3651  -14.0437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0800  -14.4570    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.7969  -14.0401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.7938  -13.2173    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.6504  -14.4559    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   26.9362  -14.0430    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0747  -11.1541    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.7910   -9.5204    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   23.3671  -10.3458    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.8490  -13.2260    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.0422  -13.0541    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.6293  -13.7685    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   26.1811  -14.3817    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.3669   -9.5208    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   22.6527  -10.7585    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   22.6497   -9.9332    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   29.8311  -11.4809    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   30.3759  -10.8624    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.9559  -10.1532    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.1518  -10.3336    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   30.2831   -9.3959    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  2  4  2  0
  1  5  1  0
  1  6  1  0
  1  7  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13  8  1  0
 12 14  1  0
 15 14  1  6
 15 16  1  0
 15 20  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 18 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 22  1  0
 24 28  1  0
 28 29  1  0
 18 30  1  1
 13 31  1  0
  8 32  1  0
 29 33  1  0
 33 34  2  0
 34 35  1  0
 35 36  1  0
 36 29  2  0
 32 37  1  0
 32 38  1  0
 32 39  1  0
 30 40  2  0
 40 41  1  0
 41 42  1  0
 42 43  1  0
 43 30  1  0
 42 44  2  0
M  END

Associated Targets(Human)

AURKB Tchem Aurora kinase B/Inner centromere protein (233 Activities)

Discover Target: AURKB

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AURKA Tchem Serine/threonine-protein kinase Aurora-A (10240 Activities)

Discover Target: AURKA

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Small molecule	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 517.49	Molecular Weight (Monoisotopic): 517.1849	AlogP: 5.00	#Rotatable Bonds: 7
Polar Surface Area: 128.50	Molecular Species: ACID	HBA: 7	HBD: 4
#RO5 Violations: 2	HBA (Lipinski): 9	HBD (Lipinski): 4	#RO5 Violations (Lipinski): 2
CX Acidic pKa: 4.79	CX Basic pKa: 5.37	CX LogP: 5.24	CX LogD: 4.68
Aromatic Rings: 4	Heavy Atoms: 37	QED Weighted: 0.26	Np Likeness Score: -0.76

References

1. (2008) Novel aminopyridine derivatives having aurora a selective inhibitory action,
2. Fancelli, Daniele D and 24 more authors. 2006-11-30 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. [PMID:17125279]
3. Yang, Jing J and 11 more authors. 2007-09-15 AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. [PMID:17495131]
4. McDermott, Ultan U and 24 more authors. 2007-12-11 Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. [PMID:18077425]
5. Weiss, Matthew M MM and 30 more authors. 2008-03-27 Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors. [PMID:18324759]
6. Shiotsu, Yukimasa Y and 16 more authors. 2009-08-20 KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. [PMID:19541823]
7. Zarrinkar, Patrick P PP and 15 more authors. 2009-10-01 AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). [PMID:19654408]
8. Shimomura, Toshiyasu T and 14 more authors. 2010-01 MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. [PMID:20053775]
9. Adams, Nicholas D ND and 31 more authors. 2010-05-27 Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. [PMID:20420387]
10. Bavetsias, Vassilios V and 21 more authors. 2010-07-22 Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. [PMID:20565112]
11. Payton, Marc M and 20 more authors. 2010-12-01 Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. [PMID:20935223]
12. Medina, Jesús R JR and 24 more authors. 2011-03-24 Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors. [PMID:21341675]
13. Mollard, Alexis A and 8 more authors. 2011-12-08 Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors. [PMID:22247788]
14. Lawrence, Harshani R and 14 more authors. 2012-09-13 Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors. [PMID:22803810]
15. Elkins, Jonathan M; Santaguida, Stefano; Musacchio, Andrea and Knapp, Stefan. 2012-09-13 Crystal structure of human aurora B in complex with INCENP and VX-680. [PMID:22920039]
16. Glaser, Keith B KB and 22 more authors. 2012-12 Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. [PMID:22935731]
17. Weïwer, Michel M and 12 more authors. 2012-12-13 A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. [PMID:23256033]
18. Li, Jie J and 6 more authors. 2013-07 A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity. [PMID:23707920]
19. Shiao, Hui-Yi HY and 18 more authors. 2013-07-11 Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor. [PMID:23808327]
20. Sampson, Peter B PB and 23 more authors. 2015-01-08 The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents. [PMID:24867403]
21. Alder, Catherine M CM and 18 more authors. 2013-10-10 Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy. [PMID:24900590]
22. Jagtap, Ajit Dhananjay AD and 8 more authors. 2014-10-06 Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia. [PMID:25089810]
23. Carry, Jean-Christophe JC and 32 more authors. 2015-01-08 SAR156497, an exquisitely selective inhibitor of aurora kinases. [PMID:25369539]
24. An, Ying Y and 7 more authors. 2016-07-01 Design and synthesis of novel benzoxazole analogs as Aurora B kinase inhibitors. [PMID:27209235]
25. Klaeger, Susan S and 47 more authors. 2017-12-01 The target landscape of clinical kinase drugs. [PMID:29191878]
26. Barker, Michael D MD and 11 more authors. 2018-11-15 Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease. [PMID:30249354]
27. Narayan, Satya S and 7 more authors. 2019-01-01 ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. [PMID:30384048]
28. Fan, Chengcheng and 7 more authors. 2020-03-15 Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition. [PMID:32058239]
29. Lakkaniga, Naga Rajiv and 5 more authors. 2020-10-01 Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression. [PMID:32717530]

6-((trans-4-(2-fluoro-3-(trifluorometh-yl)phenoxy)-1-(5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)cyclohexyl)methyl)-N-1H-pyrazol-3-ylpyridin-2-amine trifluoroacetate

Names and Identifiers

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source